Sangrix
SGRX
2 hedge funds and large institutions have $117K invested in Sangrix in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
0.07% more ownership
Funds ownership: 0.27% → 0.34% (+0.07%)
0% more funds holding
Funds holding: 2 → 2 (0)
0% more capital inflows, than outflows
Capital inflows: $28.4K | Capital outflows: $28.4K
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Virtu Financial
New York
|
+$28.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$28.4K |
SGRX Hedge Fund Activity: Q3 2022 in Review
2 of the 5,834 institutional investors tracked by Wall St. Rank reported a position in Sangrix (SGRX) for Q3 2022, worth a combined $117K — up 14% from $103K a quarter earlier.
Fund positioning in SGRX was balanced in Q3 2022: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $28.4K. The largest seller was Citadel Advisors, exiting entirely with an estimated $28.4K sold.
- 2 institutional investors held Sangrix (SGRX) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $117K of Sangrix stock for Q3 2022, up 14% quarter-over-quarter.
- 1 fund opened new Sangrix positions in Q3 2022 and 1 closed out, a net change of 0 holders.
- The largest Sangrix buyer in Q3 2022 was Virtu Financial, an estimated $28.4K added.
- The largest Sangrix seller in Q3 2022 was Citadel Advisors, an estimated $28.4K sold.
Based on aggregated 13F filings for Q3 2022.